# Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox

> **NCT02009384** · PHASE2 · TERMINATED · sponsor: **University of Louisville** · enrollment: 2 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02009384
- **Lead sponsor:** University of Louisville
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** low enrollment r/t requirement of prior treatment with denileukin diftitox
- **Last updated:** 2021-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02009384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02009384, "Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02009384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*